Selective gelatinase blockage ameliorates acute DSS colitis.

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Matrix metalloproteinases (MMPs), specifically MMP-2 and MMP-9, are elevated in intestinal inflammation and inflammatory bowel diseases (IBD).
• MMPs play a role in the inflammatory cycle, potentially exacerbating IBD pathology.

Purpose of the Study:

• To evaluate the therapeutic potential of doxycycline (nonselective MMP inhibitor) and RO28-2653 (selective gelatinase inhibitor) in a DSS-induced colitis model.
• To assess the impact of MMP inhibition on clinical and histopathological features of colitis, immune cell infiltration, and bacterial colonization.

Main Methods:

• Acute DSS colitis was induced in experimental models.
• Animals were treated with doxycycline, RO28-2653, or placebo for 8 days.
• Clinical colitis scores, histopathological changes, IL-6 secretion, immune cell influx, and Escherichia coli colonization were analyzed.

Main Results:

• Both doxycycline and RO28-2653 ameliorated colitis pathology, with RO28-2653 showing superior efficacy.
• MMP inhibition led to reduced histopathological damage, downregulated IL-6 secretion, and diminished pro-inflammatory immune cell infiltration.
• RO28-2653 prevented the overgrowth of potentially pro-inflammatory Escherichia coli in the colon without affecting the commensal microbiota.

Conclusions:

• Selective gelatinase inhibition with RO28-2653 offers a promising therapeutic strategy for IBD by disrupting the MMP-driven inflammatory cycle.
• RO28-2653 demonstrates efficacy in managing colitis symptoms and preventing dysbiosis, independent of direct antibacterial activity.
• These findings highlight RO28-2653 as a key candidate for developing novel interventions for human IBD.